TomoTherapy announces retirement of Paul Reckwerdt as president, director

[PRESS RELEASE]

Madison, Wis. - TomoTherapy has announced that co-founder Paul J. Reckwerdt will retire as president and relinquish his board directorship effective Dec. 31, 2008.

Reckwerdt plans to pursue entrepreneurial opportunities and will serve as a strategic advisor to Compact Particle Acceleration Corporation (CPAC), which is developing a compact proton therapy system in partnership with TomoTherapy.

Fred Robertson, M.D., has been appointed by the TomoTherapy Board of Directors to assume the role of president, in addition to his current role of chief executive officer. The Board of Directors has also elected to fix the number of directors at nine, as bylaws allow, effective Jan. 1, 2009.

In 1997, Mr. Reckwerdt co-founded TomoTherapy with Rock Mackie, Ph.D., to commercialize a highly precise form of radiation therapy that the two pioneered as researchers at University of Wisconsin-Madison. Today, after only five years since clinical introduction, there are more than 200 TomoTherapy Hi Art systems treating cancer patients in hospitals and clinics around the world.

Dr. Mackie, chairman of the board for TomoTherapy, said, “Paul and I have worked together for almost two decades, and I have been honored to have him as a steadfast professional partner. I am confident that Paul's deep experience and entrepreneurial spirit will assure success in his future endeavors.” Mr. Reckwerdt added, “The experience of bringing TomoTherapy technology to market and providing an advanced treatment option for cancer patients has been rewarding beyond words. I look forward to the opportunities that lie ahead, including the support of CPAC in the development of a new tool for fighting cancer.”

About TomoTherapy

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy Hi Art treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. 

Related story

• TomoTherapy shareholder Avalon Portfolio demands change in business strategy